Free Trial
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel Free SLDB Stock Alerts

Solid Biosciences (SLDB) Financials

Solid Biosciences logo
$6.59 -0.12 (-1.79%)
As of 09:33 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Solid Biosciences

Annual Income Statements for Solid Biosciences

This table shows Solid Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -17 -39 -75 -117 -88 -72 -86 -96 -125 -174
Consolidated Net Income / (Loss)		 -24 -53 -75 -117 -88 -72 -86 -96 -125 -174
Net Income / (Loss) Continuing Operations		 -24 -53 -75 -117 -88 -72 -86 -96 -125 -174
Total Pre-Tax Income 		-24 -53 -75 -117 -88 -72 -86 -96 -125 -174
Total Operating Income		 -26 -55 -76 -119 -88 -72 -106 -104 -130 -179
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 14 8.09 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 14 8.09 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 26 55 76 119 88 86 115 104 130 179
Selling, General & Admin Expense		 5.46 15 18 25 22 27 29 28 33 39
Research & Development Expense		 20 40 58 95 65 59 78 77 96 140
Restructuring Charge		 - - 0.00 0.00 1.94 0.00 7.18 -0.06 0.00 0.00
Total Other Income / (Expense), net		 1.80 1.68 0.89 2.10 0.23 0.07 20 8.24 5.03 4.88
Interest Expense		 - - - - - - - 0.44 0.34 -0.20
Interest & Investment Income		 0.37 0.22 0.62 1.58 0.12 0.06 2.62 7.58 9.47 9.90
Other Income / (Expense), net		 1.43 1.46 0.27 0.52 0.12 0.00 18 1.10 -4.10 -5.23
Basic Earnings per Share		 ($10.14) ($2.88) ($2.25) ($2.91) ($25.50) ($10.14) ($10.10) ($4.83) ($3.06) ($1.99)
Weighted Average Basic Shares Outstanding		 1.70M 13.65M 33.26M 40.29M 3.46M 7.12M 8.51M 19.88M 40.82M 87.50M
Diluted Earnings per Share		 ($10.14) ($2.88) ($2.25) ($2.91) ($25.50) ($10.14) ($10.10) ($4.83) ($3.06) ($1.99)
Weighted Average Diluted Shares Outstanding		 1.70M 13.65M 33.26M 40.29M 3.46M 7.12M 8.51M 19.88M 40.82M 87.50M
Weighted Average Basic & Diluted Shares Outstanding		 1.70M 13.65M 33.26M 40.29M 51.94M 106.77M 19.57M 37.76M 77.49M 98.39M

Quarterly Income Statements for Solid Biosciences

This table shows Solid Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -20 -24 -25 -33 -43 -39 -39 -46 -50 -57 -55
Consolidated Net Income / (Loss)		 -20 -24 -25 -33 -43 -39 -39 -46 -50 -57 -55
Net Income / (Loss) Continuing Operations		 -20 -24 -25 -33 -43 -39 -39 -46 -50 -57 -55
Total Pre-Tax Income 		-20 -24 -25 -33 -43 -39 -39 -46 -50 -57 -55
Total Operating Income		 -22 -27 -28 -35 -40 -40 -42 -48 -49 -57 -57
Total Gross Profit		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 22 27 28 35 40 40 42 48 49 57 57
Selling, General & Admin Expense		 6.81 7.99 8.33 7.86 9.13 9.14 9.28 9.20 11 11 13
Research & Development Expense		 15 19 19 27 31 31 32 39 38 46 44
Restructuring Charge		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Other Income / (Expense), net		 1.93 2.56 2.72 2.46 -2.70 0.77 2.21 2.28 -0.38 0.57 2.59
Interest Expense		 0.10 0.10 0.09 0.08 0.08 0.07 0.06 -0.34 0.01 0.00 0.00
Interest & Investment Income		 1.76 2.65 2.57 2.33 1.93 2.30 2.97 2.59 2.05 2.06 3.22
Other Income / (Expense), net		 0.27 0.00 0.24 0.21 -4.55 -1.46 -0.69 -0.64 -2.43 -1.49 -0.64
Basic Earnings per Share		 ($1.02) ($0.64) ($0.61) ($0.79) ($1.04) ($0.59) ($0.42) ($0.48) ($0.50) ($0.52) ($0.38)
Weighted Average Basic Shares Outstanding		 19.88M 38.16M 40.93M 41.44M 40.82M 66.34M 94.14M 94.42M 87.50M 109.81M 143.69M
Diluted Earnings per Share		 ($1.02) ($0.64) ($0.61) ($0.79) ($1.04) ($0.59) ($0.42) ($0.48) ($0.50) ($0.52) ($0.38)
Weighted Average Diluted Shares Outstanding		 19.88M 38.16M 40.93M 41.44M 40.82M 66.34M 94.14M 94.42M 87.50M 109.81M 143.69M
Weighted Average Basic & Diluted Shares Outstanding		 37.76M 38.38M 38.60M 39.95M 77.49M 77.52M 77.87M 77.91M 98.39M 98.45M 107.23M

Annual Cash Flow Statements for Solid Biosciences

This table details how cash moves in and out of Solid Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -21 44 35 -10 79 -34 36 -81 6.34 -20
Net Cash From Operating Activities		 -20 -43 -70 -93 -57 -78 -98 -94 -100 -156
Net Cash From Continuing Operating Activities		 -20 -43 -70 -93 -57 -78 -98 -94 -100 -156
Net Income / (Loss) Continuing Operations		 -24 -53 -75 -117 -88 -72 -86 -96 -125 -174
Consolidated Net Income / (Loss)		 -24 -53 -75 -117 -88 -72 -86 -96 -125 -174
Depreciation Expense		 0.06 0.45 1.57 2.82 3.92 2.96 2.41 2.58 2.46 1.64
Amortization Expense		 0.51 0.21 -0.09 -0.28 -0.02 1.12 0.23 -2.41 -3.59 -1.87
Non-Cash Adjustments To Reconcile Net Income		 0.31 4.87 5.96 14 12 13 -11 11 23 25
Changes in Operating Assets and Liabilities, net		 2.79 4.43 -2.83 7.76 16 -23 -3.69 -8.87 2.85 -6.82
Net Cash From Investing Activities		 -4.05 10 -27 25 6.60 -91 59 9.69 -16 -58
Net Cash From Continuing Investing Activities		 -4.05 10 -27 25 6.60 -91 59 9.69 -16 -58
Purchase of Property, Plant & Equipment		 -0.39 -2.28 -7.78 -4.39 -0.90 -1.28 -3.02 -1.52 -0.65 -1.15
Purchase of Investments		 -26 -19 -44 -31 -0.40 -141 -183 -117 -204 -236
Sale of Property, Plant & Equipment		 - - - - 0.00 0.00 0.60 0.00 0.01 0.09
Sale and/or Maturity of Investments		 22 32 25 60 7.90 51 213 129 189 179
Net Cash From Financing Activities		 3.42 77 132 58 129 135 75 3.12 122 194
Net Cash From Continuing Financing Activities		 3.42 77 132 58 129 135 75 3.12 122 194
Repayment of Debt		 - - - - - - - 0.15 -0.14 -0.30
Repurchase of Common Equity		 0.00 -2.42 -2.17 -2.10 -3.79 - - 0.00 -5.11 0.00
Issuance of Common Equity		 0.00 0.00 134 60 132 135 73 2.97 127 195
Other Financing Activities, net		 0.00 0.00 -0.01 0.00 0.00 0.11 2.28 0.00 0.46 0.01
Cash Interest Paid		 - - - - - - - 0.38 0.00 0.00

Quarterly Cash Flow Statements for Solid Biosciences

This table details how cash moves in and out of Solid Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 25 44 -22 -31 16 130 -72 -78 -1.40 237 -138
Net Cash From Operating Activities		 -21 -25 -21 -24 -30 -32 -37 -33 -54 -47 -53
Net Cash From Continuing Operating Activities		 -21 -25 -21 -24 -30 -32 -37 -33 -54 -47 -53
Net Income / (Loss) Continuing Operations		 -20 -24 -25 -33 -43 -39 -39 -46 -50 -57 -55
Consolidated Net Income / (Loss)		 -20 -24 -25 -33 -43 -39 -39 -46 -50 -57 -55
Depreciation Expense		 0.21 0.33 1.24 0.41 0.49 0.41 0.39 0.38 0.47 0.40 0.39
Amortization Expense		 -1.15 -0.54 -1.04 -1.21 -0.80 -0.31 -0.49 -0.33 -0.75 -0.62 -1.37
Non-Cash Adjustments To Reconcile Net Income		 2.96 2.18 2.67 6.98 11 5.54 4.71 5.08 9.76 7.43 7.13
Changes in Operating Assets and Liabilities, net		 -2.51 -2.85 0.74 2.84 2.13 1.79 -2.54 7.17 -13 2.31 -3.94
Net Cash From Investing Activities		 45 -38 -5.18 -11 39 -27 -33 -45 47 45 -134
Net Cash From Continuing Investing Activities		 45 -38 -5.18 -11 39 -27 -33 -45 47 45 -134
Purchase of Property, Plant & Equipment		 -0.09 -0.15 -0.29 -0.02 -0.20 -0.13 -0.38 -0.09 -0.57 -0.17 -0.15
Purchase of Investments		 -15 -83 -20 -85 -15 -65 -63 -83 -24 -83 -152
Sale and/or Maturity of Investments		 60 45 15 75 54 38 31 38 72 128 19
Net Cash From Financing Activities		 0.51 107 5.00 3.26 6.94 190 -1.60 1.18 5.14 239 48
Net Cash From Continuing Financing Activities		 0.51 107 5.00 3.26 6.94 190 -1.60 1.18 5.14 239 48
Repayment of Debt		 0.07 0.00 -0.08 -0.12 0.06 -0.14 0.05 -0.24 0.03 0.00 0.29
Repurchase of Common Equity		 - -4.83 -0.29 - - 0.00 - - - -13 -0.75
Issuance of Common Equity		 0.44 112 5.36 3.10 6.86 190 -1.66 1.42 5.12 252 49
Other Financing Activities, net		 - 0.15 0.01 0.28 0.02 0.00 0.01 - - 0.02 0.06

Annual Balance Sheets for Solid Biosciences

This table presents Solid Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2017 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 76 103 171 232 260 165 189 233
Total Current Assets		 71 86 159 223 220 130 157 205
Cash & Equivalents		 52 76 155 119 155 74 80 60
Restricted Cash		 0.07 - - - - - 0.00 1.22
Short-Term Investments		 17 7.48 0.00 89 58 50 69 128
Prepaid Expenses		 1.50 2.78 4.16 15 5.92 6.09 8.38 16
Plant, Property, & Equipment, net		 2.43 12 8.15 6.46 9.66 6.62 4.75 4.17
Total Noncurrent Assets		 3.11 5.52 4.12 3.31 31 29 27 23
Other Noncurrent Operating Assets		 3.11 5.52 4.12 3.31 31 29 27 23
Total Liabilities & Shareholders' Equity		 76 103 171 232 260 165 189 233
Total Liabilities		 11 23 39 24 49 38 51 53
Total Current Liabilities		 11 18 24 24 23 15 30 33
Accounts Payable		 5.07 7.12 3.27 4.46 3.24 2.03 4.24 3.22
Accrued Expenses		 5.97 9.18 8.64 9.53 17 10 20 19
Other Current Liabilities		 0.23 1.97 2.21 1.53 2.58 2.32 6.17 11
Total Noncurrent Liabilities		 0.00 5.15 15 0.57 26 24 21 19
Other Noncurrent Operating Liabilities		 0.00 4.41 3.72 0.57 24 24 21 19
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -59 80 132 208 212 126 137 180
Total Preferred & Common Equity		 -59 80 132 208 212 126 137 180
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -59 80 132 208 212 126 137 180
Common Stock		 65 396 537 685 774 785 921 1,138
Retained Earnings		 -124 -316 -405 -477 -563 -659 -783 -958
Accumulated Other Comprehensive Income / (Loss)		 -0.01 0.00 0.00 -0.05 -0.07 0.02 0.05 0.05

Quarterly Balance Sheets for Solid Biosciences

This table presents Solid Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 205 185 249 231 212 344 308 274 423 421
Total Current Assets		 167 148 214 198 179 313 279 245 397 395
Cash & Equivalents		 92 49 118 96 64 211 139 61 297 159
Restricted Cash		 - - - - - - - - 0.64 0.64
Short-Term Investments		 69 94 88 94 107 96 129 175 84 218
Prepaid Expenses		 7.28 5.46 8.13 7.34 8.38 6.49 11 8.71 15 17
Plant, Property, & Equipment, net		 7.39 7.05 6.39 5.44 5.07 4.48 4.32 4.36 3.91 3.96
Total Noncurrent Assets		 30 29 28 28 27 26 25 25 22 22
Other Noncurrent Operating Assets		 30 29 28 28 27 26 25 25 22 22
Total Liabilities & Shareholders' Equity		 205 185 249 231 212 344 308 274 423 421
Total Liabilities		 41 40 38 38 45 49 50 56 49 47
Total Current Liabilities		 16 16 14 15 23 29 30 36 30 29
Accounts Payable		 2.97 1.90 1.73 2.52 3.46 6.44 4.70 8.43 5.56 4.36
Accrued Expenses		 11 11 10 9.92 13 15 17 19 19 18
Other Current Liabilities		 2.39 2.45 2.28 2.25 6.17 7.76 8.60 8.86 5.54 6.43
Total Noncurrent Liabilities		 25 25 24 23 22 21 20 20 18 18
Other Noncurrent Operating Liabilities		 25 25 23 23 22 21 20 20 18 18
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 164 144 211 193 167 294 258 218 374 374
Total Preferred & Common Equity		 164 144 211 193 167 294 258 218 374 374
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 164 144 211 193 167 294 258 218 374 374
Common Stock		 781 783 894 901 908 1,117 1,121 1,126 1,389 1,443
Retained Earnings		 -617 -638 -683 -708 -741 -823 -862 -908 -1,015 -1,069
Accumulated Other Comprehensive Income / (Loss)		 0.01 0.00 -0.00 -0.02 0.12 0.00 -0.04 0.05 -0.01 -0.11

Annual Metrics And Ratios for Solid Biosciences

This table displays calculated financial ratios and metrics derived from Solid Biosciences' official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 35,432,460.00 45,987,571.00 60,449,341.00 110,295,600.00 7,534,892.00 20,177,440.00 - 77,910,239.00
DEI Adjusted Shares Outstanding		 0.00 0.00 2,362,164.00 3,065,838.00 4,029,956.00 7,353,040.00 7,534,892.00 20,177,440.00 - 77,910,239.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -31.67 -38.24 -21.91 -9.82 -11.41 -4.76 - -2.24
Growth Metrics		 - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -18 -38 -53 -84 -62 -51 -75 -73 -91 -125
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -57.70% -66.17% -69.69%
Earnings before Interest and Taxes (EBIT)		 -24 -53 -75 -119 -88 -72 -89 -103 -134 -184
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -24 -53 -74 -116 -84 -68 -86 -103 -135 -185
Valuation Ratios		 - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -34 -57 -81 -42 -73 -74 -76 -76 -128
Efficiency Ratios		 - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.00 -4.24 0.00 -2.74 -22 0.43 -0.35 2.84 -12 -9.06
Increase / (Decrease) in Invested Capital		 0.00 -4.24 4.24 -2.74 -19 23 -0.79 3.19 -15 2.61
Book Value per Share		 $0.00 ($4.34) $0.00 $1.74 $2.19 $1.89 $28.09 $6.27 $3.44 $2.31
Tangible Book Value per Share		 $0.00 ($4.34) $0.00 $1.74 $2.19 $1.89 $28.09 $6.27 $3.44 $2.31
Total Capital		 0.00 65 0.00 81 133 208 213 126 137 180
Total Debt		 0.00 0.00 0.00 0.73 0.53 0.00 1.70 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.73 0.53 0.00 1.70 0.00 0.00 0.00
Net Debt		 0.00 -69 0.00 -83 -154 -208 -212 -124 -149 -189
Capital Expenditures (CapEx)		 0.39 2.28 7.78 4.39 0.90 1.28 2.42 1.52 0.65 1.07
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -9.77 0.00 -15 -20 -8.77 -17 -8.42 -22 -17
Debt-free Net Working Capital (DFNWC)		 0.00 59 0.00 68 134 199 197 115 127 172
Net Working Capital (NWC)		 0.00 59 0.00 68 134 199 197 115 127 172
Net Nonoperating Expense (NNE)		 5.87 15 22 34 26 22 11 23 34 49
Net Nonoperating Obligations (NNO)		 0.00 -69 0.00 -83 -154 -208 -212 -124 -149 -189
Total Depreciation and Amortization (D&A)		 0.56 0.65 1.48 2.55 3.90 4.08 2.64 0.17 -1.14 -0.24
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($152.10) ($43.20) ($33.75) $0.00 ($25.50) ($10.20) ($10.10) ($4.83) ($3.06) ($1.99)
Adjusted Weighted Average Basic Shares Outstanding		 113.26K 909.97K 2.36M 0.00 5.68M 7.36M 8.51M 19.88M 40.82M 87.50M
Adjusted Diluted Earnings per Share		 ($152.10) ($43.20) ($33.75) $0.00 ($25.50) ($10.20) ($10.10) ($4.83) ($3.06) ($1.99)
Adjusted Weighted Average Diluted Shares Outstanding		 113.26K 909.97K 2.36M 0.00 5.68M 7.36M 8.51M 19.88M 40.82M 87.50M
Adjusted Basic & Diluted Earnings per Share		 ($152.10) ($43.20) ($33.75) $0.00 ($25.50) ($10.20) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 113.26K 909.97K 2.22M 0.00 3.46M 7.12M 19.57M 37.76M 77.49M 98.39M
Normalized Net Operating Profit after Tax (NOPAT)		 -18 -38 -53 -84 -61 -51 -69 -73 -91 -125
Debt Service Ratios		 - - - - - - - - - -
Payout Ratios		 - - - - - - - - - -

Quarterly Metrics And Ratios for Solid Biosciences

This table displays calculated financial ratios and metrics derived from Solid Biosciences' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 20,177,440.00 37,756,877.00 38,379,413.00 38,595,237.00 - 77,492,959.00 77,515,377.00 77,869,071.00 77,910,239.00 98,391,314.00 98,449,606.00
DEI Adjusted Shares Outstanding		 20,177,440.00 37,756,877.00 38,379,413.00 38,595,237.00 - 77,492,959.00 77,515,377.00 77,869,071.00 77,910,239.00 98,391,314.00 98,449,606.00
DEI Earnings Per Adjusted Shares Outstanding		 -1.01 -0.64 -0.65 -0.85 - -0.51 -0.51 -0.59 -0.64 -0.58 -0.56
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
EBITDA Growth		 -39.65% 12.35% -5.48% -53.99% -95.19% -53.00% -55.32% -35.99% - -42.51% -38.85%
EBIT Growth		 -31.83% 15.40% -3.65% -53.14% -102.08% -54.56% -53.86% -39.25% - -41.64% -36.88%
NOPAT Growth		 35.59% 16.13% -3.52% -52.21% -79.19% -49.10% -50.04% -36.60% - -43.08% -37.63%
Net Income Growth		 -34.22% 19.18% -1.80% -55.98% -109.47% -61.63% -57.47% -39.88% - -44.44% -38.80%
EPS Growth		 42.70% 58.44% 51.20% 24.76% -1.96% 7.81% 31.15% 39.24% - 11.86% 9.52%
Operating Cash Flow Growth		 39.61% 10.01% 21.84% -32.47% -42.37% -26.43% -74.28% -41.18% - -48.29% -40.56%
Free Cash Flow Firm Growth		 19.78% -72.49% 18.60% -13.59% 28.58% 62.63% 13.27% -2.55% - -362.01% -179.16%
Invested Capital Growth		 904.82% 434.38% -15.75% -377.25% -510.91% -316.31% -429.61% -344.30% - 42.30% 56.81%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
EBITDA Q/Q Growth		 1.29% -18.05% -1.05% -30.78% -25.12% 7.47% -2.58% -14.50% - -13.26% 0.05%
EBIT Q/Q Growth		 3.68% -22.11% -2.57% -26.94% -27.10% 6.60% -2.10% -14.89% - -13.44% 1.33%
NOPAT Q/Q Growth		 3.67% -20.65% -3.45% -26.61% -13.40% -0.39% -4.10% -15.27% - -16.00% -0.13%
Net Income Q/Q Growth		 3.07% -19.51% -3.16% -30.52% -30.17% 7.78% -0.50% -15.95% - -13.96% 3.42%
EPS Q/Q Growth		 2.86% 37.25% 4.69% -29.51% -31.65% 43.27% 28.81% -14.29% - -4.00% 26.92%
Operating Cash Flow Q/Q Growth		 -16.35% -20.98% 14.79% -10.44% -25.04% -7.44% -17.46% 10.53% - 11.81% -11.34%
Free Cash Flow Firm Q/Q Growth		 -11.94% -39.96% 28.11% -0.85% 29.61% 26.76% -66.82% -19.25% - -22.02% -0.80%
Invested Capital Q/Q Growth		 92.35% 102.68% -48.26% -237.46% -185.08% -6.69% 21.16% -85.29% - 20.70% 40.98%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00% 100.00%
Interest Burden Percent		 92.46% 90.48% 91.01% 93.58% 95.84% 94.62% 93.14% 94.00% - 96.49% 94.45%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Return on Equity (ROE)		 -56.79% -45.75% -50.81% -65.79% -94.57% -55.30% -68.25% -86.83% - -57.37% -65.50%
Cash Return on Invested Capital (CROIC)		 -2,681.11% -1,334.47% -2,132.41% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Return on Common Equity (ROCE)		 -56.79% -45.75% -50.81% -65.79% -94.57% -55.30% -68.25% -86.83% - -57.37% -65.50%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -42.83% 0.00% 0.00% 0.00% -47.43% 0.00% 0.00% - 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -16 -19 -19 -25 -28 -28 -29 -34 -35 -40 -40
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -2.83% -2.82% -3.21% -5.16% -10.76% -4.39% -4.49% -5.96% - -4.83% -4.53%
Return On Investment Capital (ROIC_SIMPLE)		 -12.32% -8.88% -10.07% -14.75% -20.35% -9.52% -11.30% -15.44% -19.21% -10.72% -10.74%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -22 -27 -28 -35 -44 -42 -42 -49 -52 -59 -58
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -23 -27 -27 -36 -45 -41 -42 -49 -52 -59 -59
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.98 2.39 1.13 1.61 1.16 0.97 1.46 2.20 - 1.89 2.63
Price to Tangible Book Value (P/TBV)		 0.98 2.39 1.13 1.61 1.16 0.97 1.46 2.20 - 1.89 2.63
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.09 51.75 9.18 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Long-Term Debt to Equity		 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Financial Leverage		 -0.99 -0.99 -0.98 -1.01 -1.03 -1.01 -1.02 -1.06 - -1.03 -1.02
Leverage Ratio		 1.26 1.21 1.22 1.27 1.34 1.17 1.19 1.26 - 1.15 1.15
Compound Leverage Factor		 1.16 1.10 1.11 1.19 1.29 1.11 1.11 1.19 - 1.11 1.09
Debt to Total Capital		 0.00% 0.52% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.52% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Common Equity to Total Capital		 100.00% 99.48% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00% 100.00%
Debt to EBITDA		 0.00 -0.01 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Net Debt to EBITDA		 0.00 2.07 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Long-Term Debt to EBITDA		 0.00 -0.01 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Debt to NOPAT		 0.00 -0.02 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Net Debt to NOPAT		 0.00 2.96 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Long-Term Debt to NOPAT		 0.00 -0.02 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Altman Z-Score		 -3.26 4.71 -0.28 -0.95 -3.92 0.73 1.13 0.84 - 5.94 9.72
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 8.94 14.94 13.45 7.85 5.20 10.89 9.34 6.74 - 13.10 13.82
Quick Ratio		 8.52 14.37 12.95 7.49 4.92 10.66 8.98 6.50 - 12.57 13.21
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -19 -26 -19 -19 -13 -9.82 -16 -20 -37 -45 -46
Operating Cash Flow to CapEx		 -23,136.67% -16,907.38% -7,505.94% -158,053.33% -14,531.86% -25,277.78% -9,923.61% -39,378.82% - -28,624.24% -35,058.00%
Free Cash Flow to Firm to Interest Expense		 -184.11 -276.67 -214.71 -232.38 -178.83 -144.46 -273.12 0.00 - 0.00 0.00
Operating Cash Flow to Interest Expense		 -204.15 -265.18 -243.94 -289.12 -395.27 -468.38 -623.53 0.00 - 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -205.03 -266.75 -247.19 -289.30 -397.99 -470.24 -629.82 0.00 - 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 2.84 5.76 2.98 -4.10 -12 -12 -9.82 -18 -9.06 -7.19 -4.24
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Increase / (Decrease) in Invested Capital		 3.19 7.48 -0.56 -5.57 -15 -18 -13 -14 2.61 5.27 5.58
Enterprise Value (EV)		 0.25 298 27 98 11 -20 109 244 - 327 605
Market Capitalization		 124 503 218 269 160 287 377 480 - 708 984
Book Value per Share		 $6.27 $5.58 $5.04 $4.33 $3.44 $3.80 $3.33 $2.80 $2.31 $3.80 $3.80
Tangible Book Value per Share		 $6.27 $5.58 $5.04 $4.33 $3.44 $3.80 $3.33 $2.80 $2.31 $3.80 $3.80
Total Capital		 126 212 193 167 137 294 258 218 180 374 374
Total Debt		 0.00 1.10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 1.10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -124 -205 -190 -171 -149 -307 -268 -236 -189 -381 -378
Capital Expenditures (CapEx)		 0.09 0.15 0.29 0.02 0.20 0.13 0.38 0.09 0.57 0.17 0.15
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -8.42 -6.21 -7.34 -14 -22 -22 -19 -28 -17 -15 -12
Debt-free Net Working Capital (DFNWC)		 115 200 183 157 127 285 249 209 172 367 367
Net Working Capital (NWC)		 115 200 183 157 127 285 249 209 172 367 367
Net Nonoperating Expense (NNE)		 4.75 5.50 5.62 8.10 15 11 10 12 15 17 15
Net Nonoperating Obligations (NNO)		 -124 -205 -190 -171 -149 -307 -268 -236 -189 -381 -378
Total Depreciation and Amortization (D&A)		 -0.94 -0.21 0.19 -0.80 -0.32 0.10 -0.10 0.05 -0.28 -0.22 -0.97
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.02) ($0.64) ($0.61) ($0.79) ($1.04) ($0.59) ($0.42) ($0.48) ($0.50) ($0.52) ($0.38)
Adjusted Weighted Average Basic Shares Outstanding		 19.88M 38.16M 40.93M 41.44M 40.82M 66.34M 94.14M 94.42M 87.50M 109.81M 143.69M
Adjusted Diluted Earnings per Share		 ($1.02) ($0.64) ($0.61) ($0.79) ($1.04) ($0.59) ($0.42) ($0.48) ($0.50) ($0.52) ($0.38)
Adjusted Weighted Average Diluted Shares Outstanding		 19.88M 38.16M 40.93M 41.44M 40.82M 66.34M 94.14M 94.42M 87.50M 109.81M 143.69M
Adjusted Basic & Diluted Earnings per Share		 ($1.02) $0.00 $0.00 $0.00 ($1.04) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 37.76M 38.38M 38.60M 39.95M 77.49M 77.52M 77.87M 77.91M 98.39M 98.45M 107.23M
Normalized Net Operating Profit after Tax (NOPAT)		 -16 -19 -19 -25 -28 -28 -29 -34 -35 -40 -40
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -215.64 -282.73 -313.06 -426.48 -592.63 -610.50 -706.43 0.00 - 0.00 0.00
NOPAT to Interest Expense		 -152.80 -197.93 -221.04 -300.33 -372.36 -412.30 -486.42 0.00 - 0.00 0.00
EBIT Less CapEx to Interest Expense		 -216.52 -284.29 -316.31 -426.66 -595.35 -612.35 -712.72 0.00 - 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -153.68 -199.50 -224.29 -300.52 -375.08 -414.15 -492.70 0.00 - 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Augmented Payout Ratio		 0.00% -5.35% -5.64% -4.99% -4.10% -0.20% 0.00% 0.00% - -6.72% -6.59%

Financials Breakdown Chart

Key Financial Trends

Solid Biosciences (NASDAQ: SLDB) remains a development-stage biotechnology company with no reported revenue and continued significant cash consumption. The latest statements show strong liquidity following equity raises, but operating losses and research spending have expanded substantially over the past several years.

  • Strong liquidity position: As of June 30, 2026, Solid Biosciences held approximately $159.4 million in cash and $218.3 million in short-term investments, plus $0.6 million of restricted cash. Total cash and liquid investments were approximately $378.3 million.
  • Low balance-sheet leverage: Total liabilities were $46.5 million against $374.1 million of shareholders’ equity. The company reported no preferred stock and relatively limited debt-related obligations.
  • Investment income provides some offset: Interest and investment income increased to $3.2 million in Q2 2026 from $2.1 million in Q1 2025, helping partially offset operating expenses.
  • Operating losses improved modestly sequentially: Q2 2026 net loss was $54.8 million, compared with a $56.7 million loss in Q1 2026. The loss also reflected a modest improvement in earnings per share, to negative $0.38 from negative $0.52.
  • Cash reserves were largely built through financing: Solid Biosciences raised $251.9 million through common-equity issuance in Q1 2026 and another $48.9 million in Q2. These proceeds materially strengthened liquidity but do not represent internally generated cash.
  • Short-term investments are being actively managed: The company purchased $151.9 million of investments and sold or matured $18.5 million during Q2 2026. This produced a $133.6 million net investing cash outflow and shifted assets from cash into investments rather than reflecting a major operating investment in property or equipment.
  • Revenue remains at zero: Solid Biosciences reported no revenue in each of the recent income statements provided, leaving the company dependent on financing and its existing cash portfolio to fund operations.
  • Losses have widened significantly: Quarterly net loss increased from $20.3 million in Q4 2023 to $42.6 million in Q4 2024, $49.8 million in Q4 2025, and $54.8 million in Q2 2026. Total operating expenses reached $57.4 million in the latest quarter.
  • Research and development spending continues to rise: R&D expense increased from $15.5 million in Q4 2023 to $30.9 million in Q1 2025 and $44.3 million in Q2 2026. This spending may support pipeline development, but it is also driving a larger operating deficit before any commercial revenue is generated.
  • Operating cash burn is accelerating: Net cash used in operating activities rose from $20.8 million in Q3 2023 to $29.6 million in Q4 2024, $37.4 million in Q2 2025, $47.2 million in Q1 2026, and $52.6 million in Q2 2026. Continued equity funding may therefore be necessary if spending remains at current levels.

Shareholder dilution is a key risk. Weighted-average basic shares outstanding increased from 19.9 million in Q4 2023 to 143.7 million in Q2 2026, largely reflecting repeated equity financing. Although the latest capital raises improve near-term financial flexibility, they also reduce each existing shareholder’s ownership percentage and could continue if the company does not eventually generate operating revenue.

Overall, Solid Biosciences has a substantial liquidity cushion and minimal balance-sheet leverage, which are important positives for a clinical-stage biotechnology company. However, the financial trend remains characterized by zero revenue, rising R&D costs, increasing losses, accelerating cash burn and dependence on equity issuance. Investors should focus on clinical and regulatory progress, potential commercialization timelines and whether future financing can be reduced before evaluating the company’s long-term financial sustainability.

10/13/26 07:22 AM ETAI Generated. May Contain Errors.

Solid Biosciences Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Solid Biosciences' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Solid Biosciences' net income appears to be on a downward trend, with a most recent value of -$174.33 million in 2025, falling from -$23.77 million in 2016. The previous period was -$124.70 million in 2024. Check out Solid Biosciences' forecast to explore projected trends and price targets.

Solid Biosciences' total operating income in 2025 was -$179.21 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $179.21 million

Over the last 9 years, Solid Biosciences' total revenue changed from $0.00 in 2016 to $0.00 in 2025, a change of 0.0%.

In the past 12 quarters, Solid Biosciences' cash and equivalents has ranged from $49.04 million in Q3 2023 to $297.10 million in Q1 2026, and is currently $159.39 million as of their latest financial filing in Q2 2026.

Solid Biosciences had total debt of $0.00 at the end of 2025, compared with none in 2024, and none in 2016.

Over the last 9 years, Solid Biosciences' book value per share changed from 0.00 in 2016 to 2.31 in 2025, a change of 231.1%.


Related Companies

Financial statements for NASDAQ:SLDB last updated on 8/6/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel